NeoPhore Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $39.9M

  • Investors
  • 21

NeoPhore General Information

Description

Developer of novel small molecule therapies designed to treat cancer through stimulation of the immune system. The company's therapies target genetic mechanisms to create neoantigen which are known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor
  • 1 Ashley Road, Cheshire
  • Altrincham WA14 2DT
  • England, United Kingdom
+44 0330
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3rd Floor
  • 1 Ashley Road, Cheshire
  • Altrincham WA14 2DT
  • England, United Kingdom
+44 0330

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeoPhore Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 05-Jan-2024 $39.9M Completed Generating Revenue
5. Early Stage VC 09-Mar-2021 Completed Generating Revenue
4. Early Stage VC 23-Jan-2020 Completed Generating Revenue
3. Grant 27-Apr-2018 Completed Generating Revenue
2. Early Stage VC 15-Nov-2017 $3.95M $3.95M Completed Generating Revenue
1. University Spin-Out 09-May-2017 Completed Startup
To view NeoPhore’s complete valuation and funding history, request access »

NeoPhore Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B3 Ordinary
B2 Ordinary
B1 Ordinary
A Ordinary
A Ordinary 131,241 $0.012667 $43.43 $43.43 1x $43.43 5.24%
A Ordinary 56,604 $0.012667 $33.57 $33.57 1x $33.57 2.26%
To view NeoPhore’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NeoPhore Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel small molecule therapies designed to treat cancer through stimulation of the immune system. The compa
Drug Discovery
Altrincham, United Kingdom
20 As of 2026

London, United Kingdom
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeoPhore Competitors (2)

One of NeoPhore’s 2 competitors is Autolus, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Autolus Formerly VC-backed London, United Kingdom
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

NeoPhore Patents

NeoPhore Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202417501-D0 Inhibitor compounds Pending 28-Nov-2024
WO-2026115265-A1 Inhibitor compounds Pending 28-Nov-2024
AU-2024281784-A1 (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses Pending 26-May-2023
EP-4720038-A1 (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses Pending 26-May-2023
WO-2024246496-A1 (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses Inactive 26-May-2023 A61P21/02
To view NeoPhore’s complete patent history, request access »

NeoPhore Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeoPhore Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
3B Future Health Fund Venture Capital Minority
4basebio Corporation Minority
Astellas Venture Management Corporate Venture Capital Minority
Bristol-Myers Squibb Corporation Minority
Cambridge Enterprise Ventures Venture Capital Minority
You’re viewing 5 of 21 investors. Get the full list »

NeoPhore FAQs

  • When was NeoPhore founded?

    NeoPhore was founded in 2017.

  • Where is NeoPhore headquartered?

    NeoPhore is headquartered in Altrincham, United Kingdom.

  • What is the size of NeoPhore?

    NeoPhore has 20 total employees.

  • What industry is NeoPhore in?

    NeoPhore’s primary industry is Drug Discovery.

  • Is NeoPhore a private or public company?

    NeoPhore is a Private company.

  • What is the current valuation of NeoPhore?

    The current valuation of NeoPhore is .

  • What is NeoPhore’s current revenue?

    The current revenue for NeoPhore is .

  • How much funding has NeoPhore raised over time?

    NeoPhore has raised $69.2M.

  • Who are NeoPhore’s investors?

    3B Future Health Fund, 4basebio, Astellas Venture Management, Bristol-Myers Squibb, and Cambridge Enterprise Ventures are 5 of 21 investors who have invested in NeoPhore.

  • Who are NeoPhore’s competitors?

    Autolus and Adaptimmune Therapeutics are competitors of NeoPhore.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process